Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Solid Tumor, Adult 1Prostatic Neoplasms 1Lymphatic Metastasis 1

Interventions

Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Magnetic Resonance Spectroscopy 2radium Ra 223 dichloride 1peposertib 1fluoroazomycin arabinoside 1cabozantinib 1avelumab 1Radiotherapy, Image-Guided 1Radiation Dose Hypofractionation 1PITX2 protein, human 1Nomograms 1Nivolumab 1Metastasectomy 1Leuprolide 1Ipilimumab 1Indocyanine Green 1Goserelin 1Docetaxel 1DEAE-Dextran 1CTLA-4 Antigen 1Artificial Intelligence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Metastasis × peposertib × Genitourinary × Clear all
NCT04071236 2026-06-05

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡